NAD precursor supplement

Nicotinamide Riboside

Nicotinamide riboside raised whole blood NAD+ by 22%, 51% and 142% at day 14 at 100, 300 and 1000 mg a day in an 8-week trial of overweight adults, although the 100 mg group was similar to the placebo group at all time points.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Nicotinamide Riboside after one dose: 50% at ~8 h, 25% at 16 h, 12.5% at 24 h.

Drawn from the half-life in the app's model, ~8 h. The model's figures

The FDA's response letter on a food-ingredient notice describes nicotinamide riboside (NR) as "a precursor of the coenzyme nicotinamide adenine dinucleotide" and "a source of vitamin B3".2 The app files it as an oral NAD precursor supplement, with the brand name Niagen in its notes. ChromaDex, the company behind Niagen, funded the Conze trial, supplied capsules for the Elhassan and Remie trials, and is described as the supplier of NR and sponsor of the clinical study in the Trammell paper.1,3,4,5 Martens and colleagues report that "Study pills, NR standards for metabolite analyses and partial funding support were provided by ChromaDex, Inc.", and Norheim and colleagues list two authors as employees of Elysium Health who own shares in it.6,7 The app grades the evidence as moderate; its note says several randomised trials confirm a rise in NAD+, a statement the trials below support for blood NAD+ and which they do not extend to clinical benefit.

Trammell and colleagues describe NAD+ as "the consumed substrate of enzymes such as poly-ADPribose polymerases (PARPs), sirtuins and cyclic ADPribose synthetases".5 They write that animals make NAD+ "either through a de novo pathway that originates with tryptophan or via salvage pathways from three NAD+ precursor vitamins", nicotinamide, nicotinic acid and NR.5 In mice given NR by oral gavage, liver NAD+ rose more than fourfold with a peak 6 hours after the dose, and the authors state that NR "drives greater NAD+-consuming activities in liver" than mole-equivalent nicotinamide or nicotinic acid; these are mouse results.5 In their one-man pilot, Trammell and colleagues, using methods "optimized for recovery of nucleotides", state that "NR was not recovered", and Martens and colleagues were "unable to detect NR concentrations in PBMCs during either treatment condition".5,6 Christen and colleagues, in a 2026 trial and ex vivo experiments, propose that "NR and NMN are not directly absorbed in the systemic circulation but are slowly metabolized by the microbiota to NA, a very potent NAD+ precursor in whole blood".8

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~8 h
Bioavailability
90%
Typical dose
300–1000 mg/day
Route
Oral
Time to peak
~1.5 h

The second column holds the app's own figures; the third holds what the retrieved sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~8 hNo half-life for NR itself was reported in the retrieved sources; a three-dose crossover registry entry with ChromaDex as collaborator lists terminal half-life as its primary outcome and shows no posted results9
Bioavailability90%No human oral bioavailability percentage was reported in the retrieved sources; the Trammell title states NR is "uniquely and orally bioavailable in mice and humans" and the text states "NR was not recovered" in the one-man pilot5
Time to peak~1.5 hPBMC NAD+ metabolites, not NR itself: after 1,000 mg in one man, NAD+ was unaffected for the first 2.7 h, rose 2.3-fold at 4.1 h and peaked at 7.7 and 8.1 h at 2.7-fold; Conze and colleagues state that PBMC NAD+ "peak 8 hours after the administration 300 and 1000 mg of NR"5,1
Duration of NAD+ riseThe app's note says NAD+ elevation lasts ~8 h in bloodIn the 12-person single-dose study, NAAD showed "significant supplementation remaining at 24 h"; with daily dosing, whole blood NAD+ rose within 7 days at 300 and 1000 mg and was sustained for the rest of an 8-week trial5,1

The chart below is drawn from the app's half-life and time to peak; its intervals are the dosing schedules the trials reported.

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily1, twice daily6.

An illustration from a pharmacokinetic model using a half-life of 8 hours. It is not a measured level or a suggested dose.

4

Human studies

A search of PubMed for randomised trials of nicotinamide riboside and NAD+ in healthy adults returned 9 records, and a search of ClinicalTrials.gov for "nicotinamide riboside" returned 131 registry entries; the table lists nine trials chosen from these and related searches.

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Trammell and colleagues, Nature Communications 20165Controlled single-dose experiment with randomised dose order and 7-day washouts, plus a one-person pilot; ChromaDex a grant funder and sponsor512 healthy men and women; the pilot was one 52-year-old man5Single oral doses of 100, 300 and 1,000 mg, with blood and urine collected over 24 h5PBMC NAD+ rose, with NAAD, undetectable before dosing, as the most sensitive marker; no serious adverse events over 36 days of observation5
Martens and colleagues, Nature Communications 20186Randomised, double-blind, placebo-controlled crossover; ChromaDex provided pills and partial funding630 healthy people aged 55 to 79 randomised, 24 completed6500 mg twice a day for 6 weeks per phase6PBMC NAD+ about 60% above placebo; systolic blood pressure and aortic stiffness only trended lower in exploratory analyses6
Dollerup and colleagues, American Journal of Clinical Nutrition 201810Investigator-initiated, randomised, double-blind, placebo-controlled, parallel-group1040 sedentary men aged 40 to 70 with obesity101000 mg twice daily for 12 weeks10Insulin sensitivity, endogenous glucose production, and glucose disposal and oxidation were not improved; no serious adverse events due to NR10
Elhassan and colleagues, Cell Reports 20193Randomised, double-blind, placebo-controlled crossover; ChromaDex supplied capsules, and one author holds ChromaDex stock312 aged men3500 mg twice daily for 21 days, 21-day washout3Muscle NAD+ metabolome rose, mitochondrial bioenergetics not altered; four participants self-reported increased libido on NR and none on placebo3
Remie and colleagues, American Journal of Clinical Nutrition 20204Randomised, double-blinded, placebo-controlled crossover; ChromaDex supplied capsules and had no role in design, analysis or writing413 healthy overweight or obese men and women completed41000 mg/day for 6 weeks4Fat-free mass 62.65% against 61.32% (P = 0.02); no effect on insulin sensitivity or mitochondrial function4
Conze and colleagues, Scientific Reports 20191Randomised, double-blind, placebo-controlled, parallel-group; funded by ChromaDex1140 overweight adults aged 40 to 60 enrolled1100, 300 or 1000 mg/day against placebo for 8 weeks1Whole blood NAD+ up 22%, 51% and 142% at day 14; 95 adverse events in 61 participants, none serious, no flushing1
Brakedal and colleagues, NADPARK, Cell Metabolism 202211Double-blinded phase I randomised trial; two authors filed a patent application on NR in Parkinson's disease1130 newly diagnosed, treatment-naive people with Parkinson's disease111,000 mg NR or placebo for 30 days11Well tolerated, with a significant but variable rise in cerebral NAD; in NR recipients showing increased brain NAD, altered cerebral metabolism was associated with "mild clinical improvement"; authors call for larger trials11
Norheim and colleagues, Nature Aging 20247Randomised, double-blind, placebo-controlled; two authors are Elysium Health employees with shares740 people with stable COPD, plus lung-healthy controls71 g twice a day for 6 weeks, follow-up 12 weeks later7Sputum IL-8 difference -52.6% (95% CI -75.7% to -7.6%; P = 0.030), with baseline IL-8 higher in the NR group and the authors advising caution because of the small sample size and large CIs; whole blood NAD+ increased by more than twofold and had returned to baseline at follow-up; plasma IL-6 unchanged and no effects on lung function or symptom severity; no serious adverse events7
Christen and colleagues, Nature Metabolism 20268Randomised, open-label, placebo-controlled; authors are employees of Nestlé Research or Nestlé Health Science, except one at Cryptobiotix SA865 healthy adults analysed, mean age 34.7 years8NR 1 g/day for 14 days (n = 16 analysed)8Whole blood NAD+ about 2-fold higher than placebo; three adverse events probably related to the product across all arms8

Deeper analysis: Trammell and colleagues, 2016

Trammell and colleagues, whose authors include ChromaDex employees, reported in Nature Communications in 2016 a one-person pilot, mouse experiments and a 12-person single-dose study conducted by KGK Synergize.5 In the pilot, a 52-year-old man took 1,000 mg each morning for seven days, and his PBMC NAD+ rose from about 18.5 µM to a peak near 50 µM, with NAAD rising at least 45-fold from below 20 nM.5 In the 12-person study, the average NAAD concentration at 8 hours was "0.56±0.26, 0.74±0.27 and 1.24±0.51 μM" at 100, 300 and 1,000 mg.5 The null results were that NR "did not produce a statistically significant all-dose elevation of NMN" or nicotinamide at any time point, and that nicotinamide showed no tendency to rise with dose.5 On adverse events, two people self-reported flushing at the 300 mg dose but not at 100 or 1,000 mg, two reported feeling hot at 1,000 mg, and there were no serious adverse events.5 The authors state that "blood samples from people exhibited greater variation, due to differing baseline levels of metabolites and variable pharmacokinetics", and that "future experiments will incorporate a validated flushing symptom questionnaire".5 Funding came from the Roy J. Carver Trust, ChromaDex and the National Institutes of Health, three authors own ChromaDex stock, one consults for ChromaDex, and one is chief scientific adviser of ProHealthspan, which sells NR supplements.5

Deeper analysis: Conze and colleagues, 2019

Conze, Brenner and Kruger reported the trial in Scientific Reports in 2019; two authors are ChromaDex employees, one is the inventor of intellectual property licensed by ChromaDex and its chief scientific adviser, and "ChromaDex funded the study".1 Participants had a body mass index of 25 to 30, were randomised by simple randomisation to 100, 300 or 1000 mg a day or placebo after a 2-week run-in, and took the capsules after breakfast.1 The primary outcome was urinary MeNAM, and "the study was powered for a secondary outcome of elevation of blood NAD+".1 Whole blood NAD+ at day 56 was 10% ± 4%, 48 ± 8% and 139 ± 19% above baseline at 100, 300 and 1000 mg, while the 100 mg group was "similar to the placebo group at all time points" and the placebo group had small but significant decreases from baseline.1 Seven participants did not complete the study, one of them from the placebo group because of nausea, and missing values were imputed with last observation carried forward.1 Ninety-five adverse events were reported by 61 participants, there were "no serious AEs or reports of flushing", and "the type, incidence and severity of the AEs were similar across the different groups".1 Possibly related events were few in each group: leg pain and high blood pressure at 100 mg, nausea and muscle pain at 300 mg, sore back, muscle soreness and nausea at 1000 mg, and rash, raised liver function tests, nausea and upset stomach (the one moderate event) on placebo; the authors report that NR "did not elevate low density lipoprotein cholesterol or dysregulate 1-carbon metabolism".1 Some haematology differences occurred at day 56, including increases in mean corpuscular volume, mean corpuscular hemoglobin and red cell distribution width only in the 1000 mg group, and the authors describe the differences as not dose-dependent, within the healthy clinical reference ranges and "not clinically meaningful or an AE".1 The authors name as limitations that "it was conducted in predominantly white, middle-aged adults who consumed a diet limited in niacin equivalents".1

Deeper analysis: Martens and colleagues, 2018

Martens and colleagues, from the University of Colorado, reported the trial in Nature Communications in 2018 and registered it as NCT02921659; the authors declare no competing interests, while ChromaDex provided study pills, NR standards and partial funding.6 The participants were lean and healthy, with an average BMI of 24 ± 4 kg m−2; 30 were randomised, three left for medication or health changes or injury in the NR-first group, one in the placebo-first group, and two dropped out for side effects.6 Both of the two dropouts for side effects (headache and skin rash) occurred in the placebo phase, and "no subject dropped out during the NR treatment condition".6 NAD+ in PBMCs was about 60% above placebo (mean change 6.2 pmol per mg protein), while the rises in NADP+, nicotinamide and NMN did not reach statistical significance.6 A total of 14 treatment-emergent adverse events were reported by 7 of 30 participants; the paper says "All self-reported AEs were mild in severity" and "no serious adverse events occurred", with the NR-condition events being nausea, flushing, leg cramps, skin rash and increased bruising, one each.6 In the placebo condition the paper's table lists nine events (headache four, flushing or hot flashes two, and skin rash, fainting and drowsiness one each) against five in the NR condition.6 The blood pressure and arterial stiffness findings were exploratory: "NR tended to lower SBP and aortic stiffness", and the authors call them hypotheses for "a future larger-scale clinical trial".6

Deeper analysis: Christen and colleagues, 2026

Christen and colleagues, Nestlé Research and Nestlé Health Science, reported in Nature Metabolism in 2026 a randomised, open-label, placebo-controlled study comparing NR, NMN and nicotinamide, registered as NCT05517122.8 Of 67 enrolled, two received the wrong product, so 65 were analysed (NR n = 16, NMN n = 15, nicotinamide n = 17, placebo n = 17); mean age was 34.7 years.8 After 14 days of NR 1 g/day, whole-blood NAD+ was higher than placebo by "49.4 µM (95% confidence interval (CI), 39.5–59.3 µM", about 2-fold, with NMN similar and nicotinamide without an effect.8 The authors report that NADP+, NADPH and NADH "were not significantly changed in any of the arms" and that "the NAD+ degradation metabolites might not be a suitable surrogate for the NAD+ status of an individual".8 Three adverse events with a probable relation to the product occurred among 65 people: abdominal pain on placebo, hypotension on NR and headache on NMN.8 The paper states "Our study had several limitations", including that the ex vivo whole-blood experiment "could not capture the mild acute impact of Nam on the NAD+ metabolome"; the retrieved text lists no funder apart from the competing-interests statement.8

Deeper analysis: Remie and colleagues, 2020

Remie and colleagues reported in the American Journal of Clinical Nutrition in 2020 that 6 weeks of NR 1000 mg/d in 13 overweight or obese adults increased skeletal muscle NAD+ metabolites, affected skeletal muscle acetylcarnitine metabolism and induced minor changes in body composition and sleeping metabolic rate, while "no other metabolic health effects were observed".4 The null results listed were insulin sensitivity, mitochondrial function, liver and intramuscular lipid, cardiac energy status and ejection fraction, ambulatory blood pressure, plasma inflammation markers and energy metabolism.4 Funding included European Union and European Research Council grants, ChromaDex supplied NIAGEN and placebo capsules, and the paper states that ChromaDex "had no role in the study design, data collection, analysis, or preparation of the manuscript".4

5

Doses reported in studies and on labels

No US drug label for nicotinamide riboside was identified in DailyMed; the rows below are trial doses and one FDA letter on food use.

Table 5.1Doses reported in studies and on labels9 rows
SourceDose and routeComparatorDuration and nNote
Trammell 20165100, 300, 1,000 mg single oral dosesDoses compared with each other and with pre-dose valuesOne dose each, 7-day washouts, n = 12Pilot: 1,000 mg each morning for 7 days, n = 1
Conze 20191100, 300, 1000 mg/day, capsulesPlacebo8 weeks, 140 enrolledFour capsules daily after breakfast
Martens 20186500 mg twice a day, oralPlacebo, crossover6 weeks per phase, 30 randomised, 24 completedExploratory physiology outcomes
Dollerup 2018101000 mg twice daily (2000 mg/d)Placebo, parallel12 weeks, 40 menInsulin sensitivity not improved
Brakedal 2022111,000 mg NRPlacebo30 days, 30 people with Parkinson's diseasePhase I
Norheim 202471 g twice a dayPlacebo6 weeks, 40 with COPD plus controlsFollow-up 12 weeks later
Christen 202681 g/dayPlacebo, open-label14 days, NR n = 16 analysedNicotinamide 0.5 g/day and NMN 1 g/day in other arms
Registry NCT05617508, Alzheimer's disease121000 mg daily, or escalation up to 3000 mg dailyPlaceboStatus completedRegistry entry; no results retrieved
FDA letter GRN 000635, food use2Maximum 0.0057% by weight as consumed in listed foods; ChromaDex-estimated upper tolerable intake 180 mg/dayNot a trialEstimate from a 90-day rat study with a 100-fold safety factorCompany estimate described in the letter

The authors of the trials cited here use the words "well tolerated" or "safe" for the doses and durations they tested, and the counts of adverse events per trial are given below. Conze and colleagues recorded 95 adverse events in 61 participants over 8 weeks, none serious and no flushing, with similar type, incidence and severity across groups.1 In Trammell and colleagues' single-dose study, two people reported flushing at 300 mg and two reported feeling hot at 1,000 mg.5 In Norheim and colleagues' trial, 29 adverse events were reported by 26 participants with no difference between NR and placebo, and gastrointestinal issues occurred in 10% of those on NR and 14% on placebo.7 In Elhassan and colleagues' trial, no clinical adverse events were reported in either phase, and four of 12 men self-reported a noticeable increase in libido on NR.3 The longest trial among those described here lasted 12 weeks, so these reports do not cover longer use.10

The app lists whole blood NAD+ as the marker to monitor. Whole blood NAD+ was the measure in Conze and colleagues' trial and in Christen and colleagues' trial, which reported rises of 22% to 142% at day 14 and about 2-fold after 14 days, respectively.1,8 Martens and colleagues and Trammell and colleagues measured NAD+ in peripheral blood mononuclear cells instead, so their figures are not whole blood values.6,5 Conze and colleagues also tracked a blood count, electrolytes, HbA1c, creatinine, BUN, AST, ALT, GGT and bilirubin through the trial.1 Martens and colleagues reported that clinical laboratory values "remained within the normal reference range during both the placebo and NR conditions" in 21 of 24 completers.6 Christen and colleagues state that degradation metabolites such as MeNam rose with any precursor and "might not be a suitable surrogate for the NAD+ status of an individual".8

The FDA's letter on GRAS Notice No. GRN 000635 says the agency received the notice on March 9, 2016 and that its subject is nicotinamide riboside chloride.2 The notice covers use as a source of vitamin B3 in vitamin waters, protein shakes, nutrition bars, gum, chews and powdered beverages at a maximum level of 0.0057% by weight as consumed.2 The agency wrote that it "has no questions at this time" about ChromaDex's conclusion, and that it "has not, however, made its own determination regarding the GRAS status of the subject use of NR".2 The letter also says FDA "did not consider whether section 301(ll) or any of its exemptions apply to foods containing NR".2 Conze and colleagues describe a crystal form of NR chloride termed NIAGEN as "generally recognized as safe (GRAS) for use in foods and the subject of two New Dietary Ingredient Notifications for use in dietary supplements"; the authors include ChromaDex employees.1 A text search of the retrieved 2026 WADA Prohibited List for "nicotin", "riboside" and "NAD" returned no entry for nicotinamide riboside; its only nicotine hit is nicotine in the Monitoring Program section.13

No half-life, absolute oral bioavailability or time to peak for NR itself was identified in the retrieved sources, and the registry entry for the three-dose pharmacokinetic study lists terminal half-life as its primary outcome without posted results.9 How NR reaches blood cells in people is not settled: Christen and colleagues propose a gut-microbiome route through nicotinic acid, while Trammell and colleagues did not recover NR in their one-man pilot and Martens and colleagues could not detect NR in PBMCs.8,5,6 Whether a rise in blood NAD+ leads to a clinical benefit is not settled by the trials described: Dollerup and Remie report no improvement in insulin sensitivity, and the Martens blood pressure findings were exploratory trends.10,4,6 Results in Parkinson's disease (30 people) and COPD (40 people with COPD) come from trials whose authors call for larger trials or confirmation.11,7 Norheim and colleagues acknowledge that paired sputum samples could not be collected from all patients, leaving a "reduced sample size compared to our original power calculation" for the primary outcome.7 A completed Alzheimer's disease registry entry (NCT05617508) tested 1000 mg daily and a dose escalation up to 3000 mg daily, and its results were not among the retrieved sources.12

What is the half-life of nicotinamide riboside?

No half-life for nicotinamide riboside itself was reported in the retrieved sources, and the app lists about 8 hours.9

How long does nicotinamide riboside take to reach its peak?

In one man given 1,000 mg, PBMC NAD+ peaked at 7.7 and 8.1 hours after the dose, while the app lists about 1.5 hours.5 These are NAD+ values in blood cells, not NR concentrations, and the PBMC NAD+ metabolome was unaffected for the first 2.7 hours.5

What is the bioavailability of nicotinamide riboside?

No human oral bioavailability percentage was reported in the retrieved sources, and the app lists 90%.5 Christen and colleagues propose that NR is "not directly absorbed in the systemic circulation" but is slowly metabolised by gut microbiota to nicotinic acid.8

Does nicotinamide riboside raise NAD+ in people?

In placebo-controlled trials in healthy adults, NR raised NAD+ in blood: whole blood NAD+ by 22%, 51% and 142% at day 14 at 100, 300 and 1000 mg/day in Conze and colleagues' trial of overweight adults.1 Martens and colleagues reported PBMC NAD+ about 60% above placebo, and Christen and colleagues reported whole blood NAD+ about 2-fold higher than placebo.6,8 The Conze 100 mg group was "similar to the placebo group at all time points" after day 14.1

Does nicotinamide riboside cause flushing?

Conze and colleagues reported no flushing at 100, 300 or 1000 mg/day over 8 weeks.1 In Trammell and colleagues' single-dose study, two people self-reported flushing at 300 mg and two reported feeling hot at 1,000 mg.5

Did nicotinamide riboside improve insulin sensitivity in trials?

Dollerup and colleagues reported that 12 weeks of NR 2000 mg/d did not improve insulin sensitivity in 40 men with obesity.10 Remie and colleagues reported no effect on insulin sensitivity after 6 weeks of 1000 mg/d in 13 overweight or obese adults.4

Is nicotinamide riboside banned by WADA?

A text search of the retrieved WADA 2026 Prohibited List found no entry for nicotinamide riboside.13

Has the FDA reviewed nicotinamide riboside?

The FDA responded to a 2016 GRAS notice on nicotinamide riboside chloride (GRN 000635) saying it had no questions at this time about the notifier's conclusion for the listed food uses.2 The letter adds that the agency had not made its own determination of GRAS status, and no US drug label for nicotinamide riboside was identified in DailyMed.2

12

References

  1. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep 2019. PMID 31278280
  2. US Food and Drug Administration. Agency response letter, GRAS Notice No. GRN 000635 (nicotinamide riboside chloride). FDA GRAS letter
  3. Elhassan YS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep 2019. PMID 31412242
  4. Remie CME, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr 2020. PMID 32320006
  5. Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016. PMID 27721479
  6. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018. PMID 29599478
  7. Norheim KL, et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging 2024. PMID 39548320
  8. Christen S, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab 2026. PMID 41540253
  9. KGK Science Inc. A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects. ClinicalTrials.gov NCT02191462. NCT02191462
  10. Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018. PMID 29992272
  11. Brakedal B, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab 2022. PMID 35235774
  12. Haukeland University Hospital. N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease. ClinicalTrials.gov NCT05617508. NCT05617508
  13. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list